[Recent progress in therapy for migraine headache].
Takahiro
T
Iizuka
Fumihiko
F
Sakai
D000927:Anticonvulsants / Q000627:therapeutic use; D001905:Botulinum Toxins / Q000627:therapeutic use; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism; D002490:Central Nervous System / Q000503:physiopathology; D002986:Clinical Trials as Topic; D015195:Drug Design; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007211:Indoles; D015201:Meta-Analysis as Topic; D008881:Migraine Disorders / Q000209:etiology* / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D010146:Pain / Q000503:physiopathology; D010880:Piperidines; D011759:Pyrrolidines; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D015398:Signal Transduction / Q000502:physiology; D018170:Sumatriptan; D000077236:Topiramate; D014230:Triazoles; D014276:Trigeminal Nerve / Q000503:physiopathology; D014363:Tryptamines; D014664:Vasodilation
D000927:Anticonvulsants; D007211:Indoles; D010880:Piperidines; D011759:Pyrrolidines; D017366:Serotonin Receptor Agonists; D014230:Triazoles; D014363:Tryptamines; D000077236:Topiramate; C115647:eletriptan; D005632:Fructose; C093622:rizatriptan; D018170:Sumatriptan; D001905:Botulinum Toxins; D015740:Calcitonin Gene-Related Peptide; C106783:naratriptan